Objective

The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Merck & Co., Inc is a global, research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharpe & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

The EFSD/MSD European Research Programme on Novel Therapies for Type 2 Diabetes is intended to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes.

Proposals may include but are not limited to:

Mechanisms to induce "browning of adipose tissue"

Novel targets for improving skeletal muscle or adipose tissue insulin resistance

Bile acid biology as it relates to metabolic disease. This includes actions relating to glucose metabolism, lipid metabolism, energy balance and related diseases including diabetes, atherosclerosis and obesity

Lipid metabolism as it relates to insulin action

Mechanisms of glucose-dependent insulin and glucagon secretion

Requirements

Applications for an EFSD/MSDgrant are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be employed full-time at a non-profit institution and the study must be performed at their place of work.

Funding

Up to Euro 100,000

Duration

The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application.

How to apply

See document attached.

In case of interest, please contact with Research's Department no later than 8th June 2015